Psychiatrie und Psychotherapie

, Volume 4, Issue 2, pp 69–73

Erweiterung des ÖGPP Konsensus-Papiers "Substanzabhängigkeit vom Morphintyp – State-of-the-art der Erhaltungstherapie mit synthetischen Opioiden": Die Therapie mit einem Buprenorphin/Naloxon-Kombinationspräparat

  • Christian Matzenauer
  • Ekkehard Madlung-Kratzer
  • Bernadette Winklbaur
  • Gabriele Fischer
  • Christian Haring
ÖGPP-Rahmenpapier
  • 38 Downloads

Zusammenfassung

Buprenorphin wird seit vielen Jahren zur oralen Erhaltungstherapie opioidabhängiger Patienten eingesetzt. Dank seiner pharmakologischen Eigenschaften ist Buprenorphin eine langwirkende Substanz mit klar definiertem Wirkprofil bei vergleichsweise hoher Anwendungssicherheit, aber auch bekanntem Missbrauchspotential. Die Effektivität der Kombination von Buprenorphin und dem Opioid-Rezeptor-Antagonisten Naloxon in sublingualer Verabreichung konnte gezeigt werden, und Missbrauch kann in dieser Formulierung deutlich reduziert werden. Wir empfehlen daher zu prüfen, ob eine Umstellung auf das Buprenorphin-Naloxon-Kombinationsprodukt das Risikoverhalten des intravenösen Konsums reduzieren kann. Für Gravide sollte das Produkt aber keinesfalls eingesetzt werden.

Schlüsselwörter

Opiatabhängigkeit Opioiderhaltungstherapie Buprenorphin Naloxon 

Extension of the consensus statement of the Austrian Society of Psychiatry and Psychotherapy on: Dependence from Morphine-type – state-of-the-art of maintenance therapy with synthetic opioides: Treatment with a Buprenorphine/Naloxone combined formulation

Summary

Buprenorphine has been used for many years for oral maintenance therapy in opioid dependent patients. Buprenorphine is a long acting substance with a clearly defined pharmacological profile and comparatively high safety, but also a certain inherent abuse potential. The efficacy of the combination of buprenorphine with the opioid-receptor-antagonist naloxone administered sublingually was shown; and abuse can be reduced significantly in this formulation. Therefore we recommend to consider, whether a switch to the buprenorphine/naloxone-combinationformulation reduces intravenous misuse. Based on safety data, pregnant patients should be continued to be maintained on buprenorphine monotherapy.

Keywords

Opiate addiction Opioid maintenance therapy Buprenorphine Naloxone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Richards ML, Sadee W. In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method. Eur J Pharmacol 1985;114:343–353PubMedCrossRefGoogle Scholar
  2. Negus SS, Bidlack JM, Mello NK, et al. Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav Pharmacol 2002; 13:557–570PubMedGoogle Scholar
  3. Lewis JW, Husbands SM. The orvinols and related opioids-high affinity ligands with diverse efficacy profiles. Curr Pharm Des 2004;10:717–732PubMedCrossRefGoogle Scholar
  4. Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and nor-buprenorphine: Norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001;297:688–695PubMedGoogle Scholar
  5. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978;35:501–516PubMedGoogle Scholar
  6. Mégarbane B, Hreiche R, Pirnay S, et al. Does high-dose buprenorhine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol Rev 2006;25:79–85PubMedCrossRefGoogle Scholar
  7. Lai SH, Yao YJ, Lo DS. A survey of buprenorphine related deaths in Singapur. Forensic Sci Int 2006;162:80–86PubMedCrossRefGoogle Scholar
  8. Gowing L, Ali R, White J (2006) Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev (2):CD002025Google Scholar
  9. Maremmani I, Pani PP, Pacini M, et al. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Subst Abuse Treat 2004;33:91–98CrossRefGoogle Scholar
  10. Jenkinson RA, Clark NC, Fry CL, et al. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005;100:197–205PubMedCrossRefGoogle Scholar
  11. Martin WR, Eades CG, Thompson JA, et al. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976;197:517–532PubMedGoogle Scholar
  12. Kosten TR, Fiellin DA; U.S. National Buprenorphine Implementation Programme. Buprenorphine for office-based practice: consensus conference overview. Am J Addict 2004;13 (Suppl 1):1–7CrossRefGoogle Scholar
  13. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003;70 (2 Suppl):39–47CrossRefGoogle Scholar
  14. Harris DS, Mendelson JE, Lin ET, et al. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin Pharmacokinet 2004;43:329–340PubMedCrossRefGoogle Scholar
  15. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005;44:661–680PubMedCrossRefGoogle Scholar
  16. Fudala PJ, Bridge TP, Herbert S, et al.; Buprenorphine/Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349:949–958PubMedCrossRefGoogle Scholar
  17. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003;70 (2 Suppl):13–27CrossRefGoogle Scholar
  18. Stoller KB, Bigelow GE, Walsh SL, et al. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 2001;154 (3):230–242PubMedCrossRefGoogle Scholar
  19. U.S. Department of Health and Human Services (2004) Clinical guidelines for the use of buprenorphine in the treatment of addiction. DHHS Publication No. (SMA) 04-3939Google Scholar
  20. Amass L, Ling W, Freese TE, et al. Bringing burprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict 2004;13 (Suppl 1):42–66CrossRefGoogle Scholar
  21. Mintzer IL, Eisenberg M, Terra M, et al. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007;5:146–150PubMedCrossRefGoogle Scholar
  22. Amass L, Kamien JB, Mikulich SK. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 2001;61:173–181PubMedCrossRefGoogle Scholar
  23. Rapeli P, Fabritius C, Alho H, et al. Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol 2007;7:5PubMedCrossRefGoogle Scholar
  24. Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug abusers. Drug Alcohol Depend 2007;88:75–78PubMedCrossRefGoogle Scholar
  25. Jones He, Johnson RE, Jasinski DR, et al. Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone. Drug Alcohol Depend 2005;78 (1):33–38PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Christian Matzenauer
    • 1
  • Ekkehard Madlung-Kratzer
    • 2
  • Bernadette Winklbaur
    • 1
  • Gabriele Fischer
    • 1
  • Christian Haring
    • 2
  1. 1.Universitätsklinik für Psychiatrie und PsychotherapieMedizinische Universität WienWienAustria
  2. 2.Psychiatrisches Krankenhaus des Landes TirolWienAustria

Personalised recommendations